Volume 41, Issue 3 pp. 136-139

Haemophagocytic lymphohistiocytosis in Malaysian children

H Ariffin

H Ariffin

Paediatric Haematology-Oncology Unit, University of Malaya Medical Centre, Kuala Lumpur, Malaysia

Search for more papers by this author
SH Lum

SH Lum

Paediatric Haematology-Oncology Unit, University of Malaya Medical Centre, Kuala Lumpur, Malaysia

Search for more papers by this author
SA Cheok

SA Cheok

Paediatric Haematology-Oncology Unit, University of Malaya Medical Centre, Kuala Lumpur, Malaysia

Search for more papers by this author
K Shekhar

K Shekhar

Paediatric Haematology-Oncology Unit, University of Malaya Medical Centre, Kuala Lumpur, Malaysia

Search for more papers by this author
WA Ariffin

WA Ariffin

Paediatric Haematology-Oncology Unit, University of Malaya Medical Centre, Kuala Lumpur, Malaysia

Search for more papers by this author
LL Chan

LL Chan

Paediatric Haematology-Oncology Unit, University of Malaya Medical Centre, Kuala Lumpur, Malaysia

Search for more papers by this author
HP Lin

HP Lin

Paediatric Haematology-Oncology Unit, University of Malaya Medical Centre, Kuala Lumpur, Malaysia

Search for more papers by this author
First published: 17 March 2005
Citations: 13
Dr Hany Ariffin, Department of Paediatrics, University of Malaya Medical Centre, 50603 Kuala Lumpur, Malaysia. Fax: +6 3 7955 6114; email: [email protected]

Abstract

Objectives: To study the clinical presentation, therapy and outcome of children diagnosed with both primary and secondary haemophagocytic lymphohistiocytosis (HLH) at the University of Malaya Medical Centre.

Methods: All patients diagnosed with HLH between 1998 and 2004 were studied. Clinico-pathological data of these patients were prospectively collected and analysed.

Results: Thirteen consecutive patients (eight boys) with a median age of 28 months were seen. All patients presented with high-grade unremitting fever and almost all, with hepatosplenomegaly and cytopenias. Neurological manifestations, which ranged from irritability to seizures and coma, were seen in 10 (77%) patients. Other common presenting features include liver dysfunction (46%) and skin rash (38%). All patients were treated using the HLH-94 protocol chemotherapy which consisted of a combination of etoposide, dexamethasone and cyclosporine. Complete response was seen in seven patients while two required bone marrow transplantation and one developed secondary acute myeloid leukaemia. Two patients died before treatment could be commenced. Overall mortality rate in our series was 46%.

Conclusions: Haemophagocytic lymphohistiocytosis is an uncommon disease with a high fatality rate. Due to its protean clinical manifestations, it may be underdiagnosed. Early detection and prompt institution of appropriate therapy is necessary to improve the outcome in affected patients.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.